PFA herewith the Scrutinizer Report of 30th Annual general meeting of the company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited held its 30th AGM on 30th September 2025 via video conferencing (11:30 AM to 11:53 AM), with 20 public shareholders attending and 0 promoters present. All 11 resolutions were passed, covering adoption of FY25 audited financials, re-appointment of Mr. Ghanshyam Dhananjay Gavali as director, change in his designation to Managing Director, appointment of M/s Sunit M Chhatbar & Co as statutory auditor (to fill the casual vacancy left by resignation of M/s Nahar V. & Co, and for a 5-year term till 2030 AGM), regularisation of Mr. Yash Arun Chaudhary as Non-Executive Non-Independent Director, change in the company's name, alteration of the object clause, adoption of new MOA and AOA, and an increase in the borrowing limits. Shareholder participation was very low, with only 1,74,292 votes polled out of 70,02,200 outstanding shares (about 2.49%), and the promoter group holding 1,50,020 shares did not cast any vote. Most resolutions passed with 97.58% in favour and 2.42% against, while the resolution to appoint Mr. Chaudhary received 100% support.
The key corporate actions are a proposed change in the company's name, a shift in its main objects clause, and a higher borrowing limit, all of which signal a potential business reorientation or expansion that shareholders should watch. The change of statutory auditor (due to the prior auditor's resignation) and the elevation of Mr. Gavali to Managing Director are routine but worth noting. Low voting turnout and zero promoter participation may be a red flag for retail investors evaluating governance and engagement.